OBJECTIVES: The soluble epoxide hydrolase (sEH) metabolizes epoxyeicosatrienoic acids (EETs) to their less active dihydroxy derivatives. Because EETs have antiinflammatory properties, we determined whether or not inhibition of sEH attenuates disease development in the monocrotaline model of pulmonary hypertension in rats. METHODS: sEH inhibition was achieved using 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (25 mg/l) and cis- 4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (5 mg/l) administered via drinking water starting 3 days prior to monocrotaline injection (60 mg/kg). RESULTS: Monocrotaline induced the development of progressive pulmonary hypertension. sEH inhibition increased the plasma ratio of EETs to DHETs and attenuated the monocrotaline-induced increase in pulmonary artery medial wall thickness as well as the degree of vascular muscularization. Moreover, right ventricular pressure was significantly lower in the group treated with sEH inhibitors. Pulmonary sEH protein expression and sEH activity, as well as pulmonary cytochrome P450 epoxygenase activity were all impaired in monocrotaline-treated rats as compared with control animals. sEH inhibitors, however, increased the plasma ratio of EETs to dihydroxy epoxyeicosatrienoic acids. Monocrotaline induced the proliferation of pulmonary endothelial and vascular smooth muscle cells in vivo as determined by 5-Bromo-2'-deoxy-Uridine incorporation, and this effect was significantly blunted in animals treated with sEH inhibitors. Proliferation of cultured pulmonary smooth muscle cell, however, was not affected by EETs or sEH inhibitors suggesting that the in-vivo effects are a consequence of a direct EET-mediated protection against the inflammation induced by monocrotaline. CONCLUSION: sEH inhibition reduces pulmonary vascular remodeling and the development of pulmonary hypertension in the monocrotaline model of primary pulmonary hypertension in rats.
OBJECTIVES: The soluble epoxide hydrolase (sEH) metabolizes epoxyeicosatrienoic acids (EETs) to their less active dihydroxy derivatives. Because EETs have antiinflammatory properties, we determined whether or not inhibition of sEH attenuates disease development in the monocrotaline model of pulmonary hypertension in rats. METHODS:sEH inhibition was achieved using 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (25 mg/l) and cis- 4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (5 mg/l) administered via drinking water starting 3 days prior to monocrotaline injection (60 mg/kg). RESULTS:Monocrotaline induced the development of progressive pulmonary hypertension. sEH inhibition increased the plasma ratio of EETs to DHETs and attenuated the monocrotaline-induced increase in pulmonary artery medial wall thickness as well as the degree of vascular muscularization. Moreover, right ventricular pressure was significantly lower in the group treated with sEH inhibitors. Pulmonary sEH protein expression and sEH activity, as well as pulmonary cytochrome P450 epoxygenase activity were all impaired in monocrotaline-treated rats as compared with control animals. sEH inhibitors, however, increased the plasma ratio of EETs to dihydroxy epoxyeicosatrienoic acids. Monocrotaline induced the proliferation of pulmonary endothelial and vascular smooth muscle cells in vivo as determined by 5-Bromo-2'-deoxy-Uridine incorporation, and this effect was significantly blunted in animals treated with sEH inhibitors. Proliferation of cultured pulmonary smooth muscle cell, however, was not affected by EETs or sEH inhibitors suggesting that the in-vivo effects are a consequence of a direct EET-mediated protection against the inflammation induced by monocrotaline. CONCLUSION:sEH inhibition reduces pulmonary vascular remodeling and the development of pulmonary hypertension in the monocrotaline model of primary pulmonary hypertension in rats.
Authors: Gerald Simonneau; Nazzareno Galiè; Lewis J Rubin; David Langleben; Werner Seeger; Guido Domenighetti; Simon Gibbs; Didier Lebrec; Rudolf Speich; Maurice Beghetti; Stuart Rich; Alfred Fishman Journal: J Am Coll Cardiol Date: 2004-06-16 Impact factor: 24.094
Authors: Christophe Morisseau; Marvin H Goodrow; John W Newman; Craig E Wheelock; Deanna L Dowdy; Bruce D Hammock Journal: Biochem Pharmacol Date: 2002-05-01 Impact factor: 5.858
Authors: D Zhu; M Bousamra; D C Zeldin; J R Falck; M Townsley; D R Harder; R J Roman; E R Jacobs Journal: Am J Physiol Lung Cell Mol Physiol Date: 2000-02 Impact factor: 5.464
Authors: Jianxin Sun; XinXin Sui; J Alyce Bradbury; Darryl C Zeldin; Michael S Conte; James K Liao Journal: Circ Res Date: 2002-05-17 Impact factor: 17.367
Authors: Ralph Theo Schermuly; Klaus Peter Kreisselmeier; Hossein Ardeschir Ghofrani; Arun Samidurai; Soni Pullamsetti; Norbert Weissmann; Christian Schudt; Leander Ermert; Werner Seeger; Friedrich Grimminger Journal: Circ Res Date: 2004-03-18 Impact factor: 17.367
Authors: S N Batchu; S B Lee; R S Qadhi; K R Chaudhary; H El-Sikhry; R Kodela; J R Falck; J M Seubert Journal: Br J Pharmacol Date: 2011-02 Impact factor: 8.739
Authors: Jun Yang; Jennifer Bratt; Lisa Franzi; Jun-Yan Liu; Guodong Zhang; Amir A Zeki; Christoph F A Vogel; Keisha Williams; Hua Dong; Yanping Lin; Sung Hee Hwang; Nicholas J Kenyon; Bruce D Hammock Journal: Am J Respir Cell Mol Biol Date: 2015-01 Impact factor: 6.914
Authors: Changlong Zheng; Luyun Wang; Rui Li; Ben Ma; Ling Tu; Xizhen Xu; Ryan T Dackor; Darryl C Zeldin; Dao Wen Wang Journal: Am J Respir Cell Mol Biol Date: 2010-01-29 Impact factor: 6.914
Authors: Ketul R Chaudhary; Mohamed Abukhashim; Sung Hee Hwang; Bruce D Hammock; John M Seubert Journal: J Cardiovasc Pharmacol Date: 2010-01 Impact factor: 3.105
Authors: Oliver Jung; Felix Jansen; Anja Mieth; Eduardo Barbosa-Sicard; Rainer U Pliquett; Andrea Babelova; Christophe Morisseau; Sung H Hwang; Cindy Tsai; Bruce D Hammock; Liliana Schaefer; Gerd Geisslinger; Kerstin Amann; Ralf P Brandes Journal: PLoS One Date: 2010-08-04 Impact factor: 3.240